NUVB.WS (Nuvation Bio) EBITDA Margin %: 15.19% (As of Mar. 2026)


NUVB.WS Nuvation Bio Inc NUVB.WS
33 GF Score
Price $0.01
! 3 Warning Signs
View Full Analysis

What is Nuvation Bio EBITDA Margin %?

Nuvation Bio NUVB.WS 33 EBITDA Margin % is 15.19% as of Mar. 2026. GuruFocus rates NUVB.WS with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Nuvation Bio ranks worse than 51.96% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nuvation Bio's EBITDA for the three months ended in Mar. 2026 was $12.64 Mil. Nuvation Bio's Revenue for the three months ended in Mar. 2026 was $83.23 Mil. Therefore, Nuvation Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 15.19%.

Nuvation Bio  (NYSE:NUVB.WS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nuvation Bio EBITDA Margin % Related Terms

Nuvation Bio EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Nuvation Bio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvation Bio EBITDA Margin % Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -7,200.75 -300.79

Nuvation Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,714.40 -1,204.84 -371.37 -70.18 15.19

NUVB.WS vs GLUE, ATAI, BHVN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Nuvation Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's EBITDA Margin % falls into.


NUVB.WS
33GF Score
Nuvation Bio Inc NUVB.WS
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvation Bio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nuvation Bio's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-189.206/62.902
=-300.79 %

Nuvation Bio's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=12.641/83.228
=15.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 15.19% mean?
Nuvation Bio (NUVB.WS) has a EBITDA Margin % of 15.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nuvation Bio and its competitors. According to the industry distribution chart, Nuvation Bio ranks #491 out of 945 companies in the Biotechnology industry, placing it in the top 52%.
Is Nuvation Bio's EBITDA Margin % too high?
Nuvation Bio's current EBITDA Margin % is 15.19%. Based on the distribution chart, Nuvation Bio ranks #491 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's EBITDA Margin % compare to GLUE and ATAI?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #491 out of 945 companies for EBITDA Margin %. This places Nuvation Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nuvation Bio and its competitors. Nuvation Bio's current EBITDA Margin % is 15.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB.WS) has a current EBITDA Margin % of 15.19%. The current EBITDA Margin % is 15.19%. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nuvation Bio (NUVB.WS), the current EBITDA Margin % is 15.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges NUVB:USA
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score

Get the complete analysis for NUVB.WS

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price